The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: Implications for sub-regional policy

Tropical Medicine and International Health

Volumn 8, Issue 10, 2003, Pages 860-867

  Rapuoda, B ^a   Ali, A ^b   Bakyaita, N ^c   Mutabingwa, T K ^l   Mwita, A ^d   Rwagacondo, C ^e   Mugisha, V ^f   Staedke, S ^g   Snow, R W ^h,i   Watkins, W M ^j   D'Alessandro, Umberto ^k  

^a MINISTRY OF HEALTH   (Kenya)

^b National Malaria Control Programme   (Tanzania)

^c National Malaria Control Programme   (Uganda)

^d National AIDS Control Program   (Tanzania)

^e Prog Natl Lutte Contre le P   (Rwanda)

^f Epidemiology and Public Hygiene   (Rwanda)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^j UNIVERSITY OF LIVERPOOL   (United Kingdom)

^k INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^l NONE

more..

Author keywords

Amodiaquine; Antimalarial drugs; Drug policy; Drug resistance; East African Network for Monitoring Antimalarial Treatment; Sulphadoxine pyrimethamine

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; CHLOROQUINE; FANSIDAR;

DISEASE CONTROL; DRUG PRESCRIBING; DRUG RESISTANCE; MALARIA;

AFRICA; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; POLICY; PRESCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

AFRICA, EASTERN; AMODIAQUINE; ANTIMALARIALS; CHLOROQUINE; DISEASE SUSCEPTIBILITY; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HEALTH POLICY; HUMANS; MALARIA; PARASITIC SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

AFRICA;

PROTOZOA;

EID: 0142215646     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1360-2276.2003.01114.x     Document Type: Article

References (22)

1. Alnwick D (2001) Meeting the malaria challenge. Africa Health September (Suppl.), 18-19.
2. Brandling-Bennett AD, Oloo AJ, Watkins WM, Boriga DA, Kariuki DM & Collins WE (1988) Chloroquine treatment of falciparum malaria in an area of Kenya of intermediate chloroquine resistance. Transactions of the Royal Society of Tropical Medicine and Hygiene 82, 833-837.
3. Clarke D, Odialla H, Ouma J et al. (1996) A malariometric survey in Turkana District, Kenya: chemosensitivity in vivo of Plasmodium falciparum infections and identity of the vector. Transactions of the Royal Society of Tropical Medicine and Hygiene 90, 302-304.
4. East African Network for Monitoring Antimalarial Treatment (1999) EANMAT: Chairman's Column. EANMAT Newsletter 2, 1-2.
5. East African Network for Monitoring Antimalarial Treatment (2001) Monitoring Antimalarial Drug Resistance within National Malaria Control Programmes (NMCPs): the EANMAT experience. Tropical Medicine and International Health 6, 1-8.
6. East African Network for Monitoring Antimalarial Treatment (2002) RBM-EANMAT - a sub regional antimalarial drug treatment policy dialogue meeting, Kampala, 25/26 October 2001. EANMAT Newsletter 5, 4-5.
7. Hastings IM (2003) Malaria control and the evolution of drug resistance: an intriguing link. Trends in Parasitology 19, 70-73.
8. Hastings IM, Watkins WM & White NJ (2002) The evolution of drug-resistant malaria: the role of drug elimination half-life. Philosophical Transactions of the Royal Society B 357, 505-519.
9. Hay SI, Rogers DJ, Randolph SE et al. (2002) Hot topic or hot air? Climate change and malaria resurgence in African highlands. Trends in Parasitology 18, 530-534.
10. Mutabingwa T, Nzila A, Mberu E et al. (2001) Chlorproguanildapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358, 1218-1223.
11. O'Neil PM, Bray PG, Hawley SR, Ward SA & Park BK (1998) 4-Aminoquinolines - past present and future: a chemical perspective. Pharmacology and Therapeutics 77, 29-58.
12. Shretta R, Omumbo JA, Rapuoda B & Snow RW (2000) Using evidence to change antimalarial drug policy in Kenya. Tropical Medicine and International Health 5, 755-764.
13. Talisuna AO, Langi P, Bakyaita N et al. (2002) Intensity of malaria transmission, antimalarial drug use and resistance in Uganda: what is the relationship between these three factors? Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 310-317.
14. Watkins WM & Mosobo M (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half life. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 75-78.
15. Watkins WM, Sixsmith D, Spencer HC et al. (1984) Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya. Lancet i, 357-359.
16. Watkins WM, Mberu EK, Winstanley PA & Plowe C (1997) The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitology Today 13, 459-464.
17. White NJ, Nosten F, Looaresuwan S et al. (1999). Averting a malaria disaster. Lancet 353, 1965-1967.
18. WHO Secretariat to the RBM Partnership (2002) 'Implementation of new antimalarial treatment policies in Africa'. Discussion Paper for the RBM Partner's Meeting, 26-28 February 2002, WHO, Geneva.
19. World Health Organization (1996) Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Malaria in Areas with Intense Transmission. WHO/MAL/96.1077, WHO, Geneva.
20. World Health Organization (2001a) The Use of Antimalarial Drugs: Report of a WHO Informal Consultation, 13-17 November 2000. WHO/CDS/RBM/2001.33, WHO, Geneva.
21. World Health Organization (2001b) Antimalarial Drug Combination Therapy: Report of a WHO Technical Consultation, 4-5 April 2001. WHO/CDS/RBM/2001.35, WHO, Geneva.
22. World Health Organization (2002) Monitoring Antimalarial Drug Resistance: Report of a WHO Consultation, Geneva, 3-5 December 2001. WHO/CDS/RBM/2002.39, WHO, Geneva.